Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chaykovska, Lyubov ^a,b   von Websky, Karoline ^a,b   Rahnenführer, Jan ^a,b   Alter, Markus ^a,b   Heiden, Susi ^a,b   Fuchs, Holger ^c   Runge, Frank ^c   Klein, Thomas ^c   Hocher, Berthold ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; LINAGLIPTIN; MESSENGER RNA; PLACEBO; SITAGLIPTIN; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; HEART MUSCLE FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TREATMENT OUTCOME; UREMIC CARDIOMYOPATHY; ANIMAL; AREA UNDER THE CURVE; BLOOD; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS FILTRATION RATE; HEART; HEART MUSCLE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREMIA;

RATTUS;

ANIMALS; AREA UNDER CURVE; CARDIOMYOPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE 1; HEART; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NEPHRECTOMY; PIPERIDINES; PURINES; PYRAZINES; QUINAZOLINES; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES; URACIL; UREMIA;

EID: 81355124070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027861     Document Type: Article

References (40)

1. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, et al. (2005) Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
3. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, et al. (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047.
4. Ossum A, van Deurs U, Engstrom T, Jensen JS, Treiman M, (2009) The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 60: 411-417.
5. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, et al. (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34: 90-95.
6. Grieve DJ, Cassidy RS, Green BD, (2009) Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157: 1340-1351.
7. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, et al. (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78: 675-688.
8. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, et al. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28: 55-72.
9. Weir GC, Mojsov S, Hendrick GK, Habener JF, (1989) Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342.
10. Scheen AJ, (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12: 648-658.
11. Shvarts V, (2008) [New avenues for pharmacotherapy of type 2 diabetes mellitus]. Klin Med (Mosk) 86: 12-17.
12. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K, (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 38: 667-678.
13. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, et al. (2009) Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 11: 786-794.
14. Yan X, Sano M, Lu L, Wang W, Zhang Q, et al. (2010) Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 9: 70.
15. Kujal P, Vernerova Z, (2008) [5/6 nephrectomy as an experimental model of chronic renal failure and adaptation to reduced nephron number]. Cesk Fysiol 57: 104-109.
16. Horiba N, Masuda S, Takeuchi A, Saito H, Okuda M, et al. (2004) Gene expression variance based on random sequencing in rat remnant kidney. Kidney Int 66: 29-45.
17. Masuda S, (2003) Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. Drug Metab Pharmacokinet 18: 91-103.
18. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, et al. (2009) Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 200: 53-61.
19. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, et al. (2007) Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 53: 480-488.
20. Rigalleau V, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, et al. (2008) Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab 34: 482-489.
21. Willems D, Wolff F, Mekhali F, Gillet C, (2009) Cystatin C for early detection of renal impairment in diabetes. Clin Biochem 42: 108-110.
22. Amann K, Breitbach M, Ritz E, Mall G, (1998) Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022.
23. Mall G, Huther W, Schneider J, Lundin P, Ritz E, (1990) Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 5: 39-44.
24. Tyralla K, Amann K, (2003) Morphology of the heart and arteries in renal failure. Kidney Int Suppl pp. S80-83.
25. Lindsay MM, Maxwell P, Dunn FG, (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40: 136-141.
26. Rabkin R, Awwad I, Chen Y, Ashley EA, Sun D, et al. (2008) Low-dose growth hormone is cardioprotective in uremia. J Am Soc Nephrol 19: 1774-1783.
27. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, et al. (2009) Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension 54: 1313-1320.
28. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr, (2007) Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 292: R897-901.
29. Mizobuchi M, Towler D, Slatopolsky E, (2009) Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453-1464.
30. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU, (2005) Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta 1731: 179-190.
31. Ku HC, Chen WP, Su MJ, (2010) GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 382: 463-474.
32. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, et al. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53: 654-662.
33. Amori RE, Lau J, Pittas AG, (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Jama 298: 194-206.
34. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, et al. (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. Jama 301: 383-392.
35. National Institute of Diabetes and Digestive and Kidney Diseases US Renal Data Systems: USRDS 2011 annual data report: Atlas of End Stage Renal Disease in the United States. National Institutes of Health, Bethesda, Maryland, USA;http://www.usrds.org/adr.aspx.
36. Kalk P, Eggert B, Relle K, Godes M, Heiden S, et al. (2007) The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 151: 1025-1032.
37. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, et al. (2006) NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 148: 853-859.
38. Vignon-Zellweger N, Relle K, Kienlen E, Alter M, Seider P, et al. (2011) Endothelin-1 overexpression restores diastolic function in eNOS knockout mice. J Hypertens 29: 961-970.
39. Rozen S, Skaletsky H, (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.
40. Aronson JK, Dengler HJ, Dettli L, Follath F, (1988) Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1-7.